To find creative solutions to reduce the variance in the provision of MS services across England and the UK.
Variance in MS Services, for example, access to and the prescribing of disease-modifying therapies, have been well documented across England by surveys performed by the MS Society, MS Trust and the RCP. This has been backed up by data presented at the ABN in Birmingham from the NHSE Bluteq database. We and others feel this is a problem for people living with MS and is a barrier to improving outcomes for pwMS being managed by the NHS in England. To address this problem we propose holding an initial meeting of representatives from MS DMT prescribing centres across England. The aim of the meeting is to generate ideas and proposals to address and solve this problem. We envisage holding subsequent follow-on meetings to implement and test potential proposals developed as a result of this meeting.
Chairs / Steering Committee:
Gavin Giovannoni, David Rog, Gordon Mazibrada and Jeremy Hobart
Programme to be confirmed
Costs and Accommodation:
This is a free meeting and is being supported by an industry sponsorship grant. Travel and accommodation will be provided for all delegates on the night of the 1 November 2018 at the Park Regis Hotel in Birmingham.
Applied for 6 CPD external credits by the Federation of the Royal Colleges of Physicians of the United Kingdom.
We will be only accepting 2 representatives from each centre/hospital. Should we receive more than 2 applications, those applicants will be placed on a waiting list and will be contacted.
Places are confirmed on a first come basis following receipt of the completed application form and our terms and conditions must be adhered to, otherwise your place will be offered to the next available delegate.
If you have any problems opening the online form due to a firewall or other network security systems, please contact Jamie McGregor at firstname.lastname@example.org.
“Parts of the running costs of this meeting have been sponsored by Roche Products Limited and Sanofi. Roche Products Limited and Sanofi have had no control over the educational content of this activity”